Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL682267 | 0.81 | TRPA1 (0.37) | SIRT3TDP1KIF11CYP1A2CYP2E1 | |
| SCHEMBL1705592 | 0.80 | KIF11 (0.39) | TDP1KIF11ALOX5PTGS1PTGS2 | |
| SCHEMBL1310290 | 0.79 | CYP17A1 (0.44) | SIRT3TDP1KIF11CYP1A2CYP17A1 | |
| SCHEMBL29497402 | 0.79 | CYP17A1 (0.44) | SIRT3TDP1KIF11CYP1A2CYP17A1 | |
| SCHEMBL22215328 | 0.79 | SIRT3 (0.36) | SIRT3TDP1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL16477946 | 0.79 | SIRT3 (0.36) | SIRT3TDP1CYP1A2CYP2E1CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL29243690 | 0.77 | CYP17A1 (0.43) | SIRT3TDP1KIF11CYP1A2CYP17A1 | |
| SCHEMBL30493966 | 0.76 | SIRT3 (0.37) | SIRT3TDP1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL19185523 | 0.76 | TDP1 (0.34) | SIRT3TDP1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL11955155 | 0.74 | GAA (0.41) | KIF11CYP3A4ALOX5PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| CN-117580826-A | NLRP3 inflammation corpuscle inhibitor | 阿斯利康(瑞典)有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | SAIL BIOMEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | SAIL BIOMEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-5795870-A | STEROID RING WITH AMINE GROUP SIDE CHAINS | TRUSTEES OF PRINCETON UNIVERSITY (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0756601-A1 | COMPOSITIONS AND METHODS FOR CELL TRANSFORMATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1997-02-05 | — | — | EP | disclosed |
| WO-1995029186-A1 | COMPOSITIONS AND METHODS FOR CELL TRANSFORMATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | SIRT3 411/4885TDP1 3424/4885KIF11 4462/4885 |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | TP53, MDM2, TP53BP1 | SIRT3 700/4885TDP1 295/4885KIF11 3719/4885 |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | AHR, CD274, ARNT | SIRT3 2975/4885TDP1 2056/4885KIF11 4429/4885 |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, CRH | SIRT3 2771/4885TDP1 2992/4885KIF11 4772/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | SIRT3 3183/4885TDP1 3111/4885KIF11 4336/4885 |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | SIRT3 1836/4885TDP1 1022/4885KIF11 3516/4885 |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | SIRT3 1956/4885TDP1 4312/4885KIF11 4681/4885 |
| US-20080161345-A1 | Aryl Sulfonamides | CCR2, CCL2, CX3CR1 | SIRT3 1427/4885TDP1 4499/4885KIF11 4325/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | SIRT3 2608/4885TDP1 1090/4885KIF11 2054/4885 |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | APLNR, AGTR1, AGTR2 | SIRT3 4462/4885TDP1 2917/4885KIF11 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.